Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adjuvant fumavirine (vemuratinib) after surgery in EGFR-mutant NSCLC
ChiCTR2600123375Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: 3-year disease-free survival rate. Started Apr 2026; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600123375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123375.